title: [The use of laser vaporization for the treatment of benign prostatic hyperplasia].
abstract: Results of use of UroBeam laser diode in 72 patients with benign prostatic hyperplasia (BPH) were analyzed. Average prostate volume was 67.29 +/- 26.72 cm3, the duration of vaporization--69.2 +/- 23.7 min. Blood loss was minimal. In the period from 2 weeks to 4 months after surgery, 9 patients have developed acute urinary retention. In the early postoperative period, acute prostatitis was diagnosed in 7 patients and was jugulated using drug treatment. The laser vaporization of BPH led to a three-fold reduction in the severity of urinary disorders and increase the urinary flow rate. The combination of laser vaporization of the prostate with transurethral resection of the prostate allow to improve the recovery of urination after surgery.
authors.forename: D V
authors.initials: DV
authors.lastname: Ustinov
authors.forename: D P
authors.initials: DP
authors.lastname: Kholtobin
authors.forename: E V
authors.initials: EV
authors.lastname: Kul'chavenia
authors.forename: B I
authors.initials: BI
authors.lastname: Aĭzikovich
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D007610:Kallikreins / Q000097:blood; D053685:Laser Therapy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D054023:Lasers, Semiconductor; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000601:surgery*; D020728:Transurethral Resection of Prostate / Q000379:methods; D016896:Treatment Outcome; D016055:Urinary Retention / Q000209:etiology
chemical_list: C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen